Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology

28-02-2024 | Computed Tomography | original report

Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma

Authors: Changbin Wang, Ran Zhang, Xiaorong Sun, Ligang Xing

Published in: memo - Magazine of European Medical Oncology

Login to get access

Summary

Background

The purpose of this study was to assess the correlation between textural features from 18fluorodeoxyglucose positron emission tomography (18F-FDG-PET) or computed tomography (CT) and EGFR mutation status in patients with stage IV adenocarcinoma lung cancer.

Methods

In all, 71 patients who were diagnosed with stage IV adenocarcinoma lung cancer between April 2014 and August 2018 were included in this study. 18F-FDG-PET/CT scanning and EGFR mutation tests were performed before targeted molecular therapy. Textural features were extracted from manually segmented volumes of tumors, and highly dependent features were excluded. Multivariate logistic regression analysis was used to establish predictive models for detection of EGFR mutations. Receiver operating characteristic (ROC) curves were applied to evaluate areas under the curves (AUCs) of each model.

Results

Of the 71 patients, 39 (54.9%) were EGFR mutation and 32 (45.1%) showed wild-type. EGFR mutation status was significantly associated with female sex (P = 0.026). In multivariate analysis, three PET (co-occurrence contrast, intensity-size-zone low-intensity large-zone emphasis, and texture spectrum max spectrum) and two CT quantitative features (intensity-size-zone high-intensity zone emphasis and normalized co-occurrence second angular moment) were independent predictors of EGFR mutation status. The predictive model generated from combined clinical and textural features showed a better predictive value than the model from textural features alone (AUC 0.897 vs 0.864).

Conclusions

Textural features combined with clinical features could establish a model for improving the predicting power of EGFR mutation status in patients with stage IV adenocarcinoma lung cancer.
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015;65(1):5–29.
2.
von Verschuer U, Schnell R, Tessen HW, et al. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer—final results from the prospective German TLK cohort study. Lung Cancer. 2017;112:216–24.CrossRef
3.
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.CrossRefPubMed
4.
Mok TS, Wu Y‑L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMed
5.
Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Clin Pharm Ther. 2013;105(9):595–605.
6.
Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(3):839.CrossRefPubMed
7.
Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497.ADSCrossRefPubMed
8.
Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer. Cancer Res. 2004;64(24):8919.CrossRefPubMed
9.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMed
10.
Girard N, Sima CS, Jackman DM, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. 2012;39(2):366.CrossRefPubMed
11.
Rios Velazquez E, Parmar C, Liu Y, et al. Somatic mutations drive distinct imaging phenotypes in lung cancer. Cancer Res. 2017;77(14):3922–30.CrossRefPubMed
12.
13.
Yang B, Wang QG, Lu M, et al. Correlations study between (18)F-FDG PET/CT metabolic parameters predicting epidermal growth factor receptor mutation status and prognosis in lung adenocarcinoma. Front Oncol. 2019;9:589.CrossRefPubMedPubMedCentral
14.
Liu Y, Kim J, Qu F, et al. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiology. 2016;280(1):271–80.CrossRefPubMed
15.
Yano M, Sasaki H, Kobayashi Y, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol. 2006;1(5):413–6.CrossRefPubMed
16.
Zhou JY, Zheng J, Yu ZF, et al. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur Radiol. 2015;25(5):1257–66.CrossRefPubMed
17.
Kim H, Park C, Keam B, Park S, Kim M, Kim T, et al. The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors. PLoS ONE. 2017;12:e187500.CrossRefPubMedPubMedCentral
18.
Park S, Ha S, Lee S, Paeng J, Keam B, Kim T, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 2018;13:e189766.CrossRefPubMedPubMedCentral
19.
Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.ADSCrossRefPubMed
20.
Zhou B, Xu J, Tian Y, Yuan S, Li X. Correlation between radiomic features based on contrast-enhanced computed tomography images and Ki-67 proliferation index in lung cancer: A preliminary study. Thora Cancer. 2018;9(10):1235–40.CrossRef
21.
Ozkan E, West A, Dedelow JA, et al. CT gray-level texture analysis as a quantitative imaging biomarker of epidermal growth factor receptor mutation status in adenocarcinoma of the lung. Am J Roentgenol. 2015;205(5):1016–25.CrossRef
22.
Liu Y, Kim J, Balagurunathan Y, et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin Lung Cancer. 2016;17(5):441–448 e446.
23.
Wang S, Shi J, Ye Z, et al. Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning. Eur Respir J. 2019;53(3).
24.
Locatelli-Sanchez M, Couraud S, Arpin D, Riou R, Bringuier P‑P, Souquet P‑J. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: Exons 18–21 sequencing results of 753 patients and subsequent clinical outcomes. Lung. 2013;191(5):491–9.CrossRefPubMed
25.
Cheng N‑M, Fang DY‑H, Tung-Chieh CJ, et al. Textural Features of Pretreatment 18F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T‑Stage Oropharyngeal Squamous Cell Carcinoma. J Nucl Med. 2013;54:1703–9.CrossRefPubMed
26.
Stephen Y, Keisha M, Michalis A, et al. Comparison of Texture Features Derived from Static and Respiratory-Gated PET Images in Non-Small Cell Lung Cancer. Plos One. 2014;9(12:e115510.
27.
Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJR. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40(1):133–40.CrossRefPubMed
28.
W‑s L, L‑j Z. Pang Q‑s, Yuan Z‑y, Li B, Wang P. Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol. 2013;31(1:771.
29.
Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med. 2009;24(1):48–54.CrossRefPubMedPubMedCentral
30.
da Cunha SG, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6(1):49–69.CrossRef
31.
Park S, Ha S, Lee S‑H, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 2018;13(1):e189766–e189766.CrossRefPubMedPubMedCentral
Metadata
Title
Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma
Authors
Changbin Wang
Ran Zhang
Xiaorong Sun
Ligang Xing
Publication date
28-02-2024
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-00961-1
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits